Investors & Media

What's new.

Press releases

Press releases.

August 20th 2024

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

August 14th 2024

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

August 7th 2024

Immutep to Participate in Upcoming Investor Conferences

more

Investor updates

Investor updates.

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

November 17th 2022

Investor Update - November 2022

more

Analyst reports

Analyst reports.

September 11th 2024

Capital One - Exciting HARMONi-2 Data at WCLC Shouldn’t Discount Efti/Pembro Combo in NSCLC; Reiterate OW; $8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 11th 2024

CLSA - Head & neck take two: Hopeful on durability data at ESMO, may support positive outlook; Retain Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

September 9th 2024

Wilsons - Summit data relevance limited; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

more